TORONTO, ONTARIO–(Marketwire – April 11, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Cancer Therapeutics (“ACT”) today announced Arch scientists have successfully completed proof of principle studies in the area of targeting brain tumour initiating cells.
